Boston Scientific Corp. plans to introduce two dozen new products this year, part of a plan by its new executives to broaden the device maker’s business base and increase earnings at a double-digit rate over the next five years. That ambitious agenda was laid out by Boston Scientific’s new chief executive, Hank Kucheman, and new president, Mike Mahoney, to investors at the 30th annual J.P. Morgan Healthcare Conference in San Francisco. While profits at the Natick, Mass., company have been squeezed in recent years by reimbursement cuts in its core markets of cardiac and endoscopy devices, investments in new products and new geographic markets should enable Boston Scientific to grow in the coming years, they said.
